{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:04:15Z","timestamp":1789596255992,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40801-025-00533-7","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:52:14Z","timestamp":1769158334000},"page":"111-120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and Effectiveness of a Fixed-Dose Combination of Cephalexin Extended Release and Clavulanate Potassium in Bacterial Sore Throat and Uncomplicated Skin and Soft-Tissue Infections: A Multicentre, Open-Label, Phase IV Study in India"],"prefix":"10.1007","volume":"13","author":[{"given":"Sunil","family":"Panda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrinivas","family":"Chavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth","family":"Bipinkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshal","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipak","family":"Solanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandodari","family":"Rajurkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapan","family":"Behera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5481-7780","authenticated-orcid":false,"given":"Supriya","family":"Sonowal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipak","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin","family":"Ghadge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit","family":"Lakhwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyog","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadhna","family":"Joglekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"533_CR1","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/978-3-319-19674-9_52","volume-title":"Molecular pathology in clinical practice","author":"CC Ginocchio","year":"2016","unstructured":"Ginocchio CC. Respiratory infections. In: Leonard D, editor. Molecular pathology in clinical practice. Cham: Springer; 2016. p. 755\u201378. https:\/\/doi.org\/10.1007\/978-3-319-19674-9_52."},{"issue":"24","key":"533_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11061369","volume":"11","author":"LF Valladales-Restrepo","year":"2023","unstructured":"Valladales-Restrepo LF, Aristiz\u00e1bal-Carmona BS, Giraldo-Correa JA, Acevedo-Medina LF, Valencia-S\u00e1nchez L, Acevedo-L\u00f3pez DT, et al. Antibiotic management of uncomplicated skin and soft tissue infections in the real world. Microorganisms. 2023;11(24):1369. https:\/\/doi.org\/10.3390\/microorganisms11061369.","journal-title":"Microorganisms"},{"key":"533_CR3","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.21276\/sjams.2016.4.6.31","volume":"4","author":"SP Masavkar","year":"2016","unstructured":"Masavkar SP, Naikwadi A. Study of incidence of upper respiratory tract infections in urban and rural population. Sch J Appl Med Sci. 2016;4:2023\u20136. https:\/\/doi.org\/10.21276\/sjams.2016.4.6.31.","journal-title":"Sch J Appl Med Sci"},{"issue":"7","key":"533_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0265933","volume":"17","author":"P Ghimire","year":"2022","unstructured":"Ghimire P, Gachhadar R, Piya N, Shrestha K, Shrestha K. Prevalence and factors associated with acute respiratory infection among under-five children in selected tertiary hospitals of Kathmandu Valley. PLoS ONE. 2022;17(7):e0265933. https:\/\/doi.org\/10.1371\/journal.pone.0265933.","journal-title":"PLoS ONE"},{"issue":"37","key":"533_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100986","volume":"28","author":"X Jin","year":"2021","unstructured":"Jin X, Ren J, Li R, Gao Y, Zhang H, Li J, et al. Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019. EClinicalMedicine. 2021;28(37):100986. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100986.","journal-title":"EClinicalMedicine."},{"issue":"10","key":"533_CR6","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.1093\/cid\/cis629","volume":"55","author":"ST Shulman","year":"2012","unstructured":"Shulman ST, Bisno AL, Clegg HW, Gerber MA, Kaplan EL, Lee G, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis. 2012;55(10):e86-102. https:\/\/doi.org\/10.1093\/cid\/cis629.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"533_CR7","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1093\/cid\/ciu444","volume":"59","author":"DL Stevens","year":"2014","unstructured":"Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-52. https:\/\/doi.org\/10.1093\/cid\/ciu444.","journal-title":"Clin Infect Dis"},{"issue":"533","key":"533_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/pgmj.46.533.157","volume":"46","author":"A Bailey","year":"1970","unstructured":"Bailey A, Walker A, Hadley A, James DG. Cephalexin: a new oral antibiotic. Postgrad Med J. 1970;46(533):157\u20138. https:\/\/doi.org\/10.1136\/pgmj.46.533.157.","journal-title":"Postgrad Med J"},{"key":"533_CR9","unstructured":"Herman TF, Hashmi MF. Cephalexin [updated 2023 Aug 17]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK549780\/. Accessed 25 Aug 2025."},{"issue":"18","key":"533_CR10","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2147\/IDR.S483953","volume":"10","author":"BN Justine","year":"2025","unstructured":"Justine BN, Mushi MF, Silago V, Igembe Z, Muyombe J, Kishengena PP, et al. Antimicrobial resistance surveillance of skin and soft tissue infections: hospital-wide bacterial species and antibiograms to inform management at a zonal tertiary hospital in Mwanza, Tanzania. Infect Drug Resist. 2025;10(18):791\u2013802. https:\/\/doi.org\/10.2147\/IDR.S483953.","journal-title":"Infect Drug Resist."},{"key":"533_CR11","unstructured":"Institute of Health Metrics and Evaluation. The burden of antimicrobial resistance (AMR) in India. 2023. https:\/\/www.healthdata.org\/sites\/default\/files\/2023-09\/India.pdf. Accessed 24 Nov 2025."},{"issue":"5","key":"533_CR12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.2428","volume":"10","author":"G Nepal","year":"2018","unstructured":"Nepal G, Bhatta S. Self-medication with antibiotics in WHO southeast Asian region: a systematic review. Cureus. 2018;10(5):e2428. https:\/\/doi.org\/10.7759\/cureus.2428.","journal-title":"Cureus"},{"issue":"4","key":"533_CR13","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1039\/d1md00200g","volume":"12","author":"M Mora-Ochomogo","year":"2021","unstructured":"Mora-Ochomogo M, Lohans CT. \u03b2-lactam antibiotic targets and resistance mechanisms: from covalent inhibitors to substrates. RSC Med Chem. 2021;12(4):1623\u201339. https:\/\/doi.org\/10.1039\/d1md00200g.","journal-title":"RSC Med Chem"},{"key":"533_CR14","unstructured":"Cephalexin extended release and clavulanate potassium tablets. Sporidex CV 375 mg+125mg\/750 mg+125 mg. Prescribing information. Mumbai: Sun Pharmaceutical Industries Limited; 2019."},{"issue":"2","key":"533_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1592\/phco.20.3.199.34780","volume":"20","author":"KJ Madaras-Kelly","year":"2000","unstructured":"Madaras-Kelly KJ, Arbogast R, Jue S. Increased therapeutic failure for cephalexin versus comparator antibiotics in the treatment of uncomplicated outpatient cellulitis. Pharmacotherapy. 2000;20(2):199\u2013205. https:\/\/doi.org\/10.1592\/phco.20.3.199.34780.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"533_CR16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1128\/AAC.10.2.219","volume":"10","author":"MH Richmond","year":"1976","unstructured":"Richmond MH, Wotton S. Comparative study of seven cephalosporins: susceptibility to beta-lactamases and ability to penetrate the surface layers of Escherichia coli. Antimicrob Agents Chemother. 1976;10(2):219\u201322. https:\/\/doi.org\/10.1128\/AAC.10.2.219.","journal-title":"Antimicrob Agents Chemother"},{"key":"533_CR17","doi-asserted-by":"crossref","unstructured":"Karadkhele A, Puppalwar G, Rattan A, Dharmadhikari S, Khandhedia C, Markandeywar N, et al. In-vitro study to compare minimum inhibitory concentrations of cephalexin-clavulanate (3:1 and 6:1) with cephalexin alone against methicillin-sensitive Staphylococcus aureus (MSSA). Abstracts at CIDSCON 2024. J Clin Infect Dis Soc. 2024; 2(3):163\u2013292.","DOI":"10.4103\/CIDS.CIDS_56_24"},{"issue":"1","key":"533_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s40801-023-00406-x","volume":"11","author":"K Banerjee","year":"2024","unstructured":"Banerjee K, Kakkar A, Shamsi KA, Bansal D, Mathur P, Potode NM, et al. Effectiveness of oral cephalexin-clavulanic acid, cefuroxime, and amoxicillin-clavulanic acid in the management of dental infections: a real-world, retrospective, electronic medical record-based study in India. Drugs Real World Outcomes. 2024;11(1):53\u201368. https:\/\/doi.org\/10.1007\/s40801-023-00406-x.","journal-title":"Drugs Real World Outcomes"},{"key":"533_CR19","unstructured":"European Medicines Agency. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-revision-3_en.pdf. Accessed 24 Nov 2025."},{"issue":"6","key":"533_CR20","doi-asserted-by":"publisher","first-page":"425","DOI":"10.7326\/m15-1840","volume":"164","author":"AM Harris","year":"2016","unstructured":"Harris AM, Hicks LA, Qaseem A, High Value Care Task Force of the American College of Physicians, Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016;164(6):425\u201334. https:\/\/doi.org\/10.7326\/m15-1840.","journal-title":"Ann Intern Med"},{"issue":"10325","key":"533_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","unstructured":"Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(21)02724-0.","journal-title":"Lancet"},{"key":"533_CR22","unstructured":"World Health Organization. Global antibiotic resistance surveillance report 2025: Summary. 2025. https:\/\/www.who.int\/publications\/i\/item\/B09585. Accessed 24 Nov 2025."},{"issue":"3","key":"533_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.otorri.2015.01.001","volume":"66","author":"JM Cots","year":"2015","unstructured":"Cots JM, Al\u00f3s JI, B\u00e1rcena M, Boleda X, Ca\u00f1ada JL, G\u00f3mez N, et al. Recommendations for management of acute pharyngitis in adults. Acta Otorrinolaringol Esp. 2015;66(3):159\u201370. https:\/\/doi.org\/10.1016\/j.otorri.2015.01.001.","journal-title":"Acta Otorrinolaringol Esp"},{"issue":"1","key":"533_CR24","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s12070-011-0437-x","volume":"66","author":"S Donde","year":"2014","unstructured":"Donde S, Mishra A, Kochhar P. Azithromycin in acute bacterial upper respiratory tract infections: an Indian non-interventional study. Indian J Otolaryngol Head Neck Surg. 2014;66(1):225\u201330. https:\/\/doi.org\/10.1007\/s12070-011-0437-x.","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"issue":"2","key":"533_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s13205-016-0473-z","volume":"6","author":"LM Wang","year":"2016","unstructured":"Wang LM, Qiao XL, Ai L, Zhai JJ, Wang XX. Isolation of antimicrobial resistant bacteria in upper respiratory tract infections of patients. 3 Biotech. 2016;6(2):166. https:\/\/doi.org\/10.1007\/s13205-016-0473-z.","journal-title":"3 Biotech"},{"key":"533_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3989781","volume":"2022","author":"N Amatya","year":"2022","unstructured":"Amatya N, Paudel G, Saud B, Wagle S, Shrestha V, Adhikari B. Prevalence of\u00a0Moraxella catarrhalis\u00a0as a nasal flora among healthy kindergarten children in Bhaktapur, Nepal. Interdiscip Perspect Infect Dis. 2022;2022:3989781. https:\/\/doi.org\/10.1155\/2022\/3989781.","journal-title":"Interdiscip Perspect Infect Dis"},{"issue":"1","key":"533_CR27","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/jac\/dks355","volume":"68","author":"SJ Chandy","year":"2013","unstructured":"Chandy SJ, Thomas K, Mathai E, Antonisamy B, Holloway KA, Stalsby Lundborg C. Patterns of antibiotic use in the community and challenges of antibiotic surveillance in a lower-middle-income country setting: a repeated cross-sectional study in Vellore, South India. J Antimicrob Chemother. 2013;68(1):229\u201336. https:\/\/doi.org\/10.1093\/jac\/dks355.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"533_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1155\/2008\/846453","volume":"19","author":"V Ki","year":"2008","unstructured":"Ki V, Rotstein C. Bacterial skin and soft tissue infections in adults: a review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. Can J Infect Dis Med Microbiol. 2008;19(2):173\u201384. https:\/\/doi.org\/10.1155\/2008\/846453.","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"4","key":"533_CR29","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/jpids\/piu030","volume":"3","author":"GP DeMuri","year":"2014","unstructured":"DeMuri GP, Wald ER. The group A streptococcal carrier state reviewed: still an enigma. J Pediatr Infect Dis Soc. 2014;3(4):336\u201342. https:\/\/doi.org\/10.1093\/jpids\/piu030.","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"8","key":"533_CR30","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025247","volume":"6","author":"K Bush","year":"2016","unstructured":"Bush K, Bradford PA. \u03b2-Lactams and \u03b2-lactamase inhibitors: an overview. Cold Spring Harb Perspect Med. 2016;6(8):a025247. https:\/\/doi.org\/10.1101\/cshperspect.a025247.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"533_CR31","unstructured":"Uto LR, Gerriets V. Clavulanic acid [updated 2023 May 29]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. https:\/\/www.ncbi.nlm.nih.gov\/sites\/books\/NBK545273\/. Accessed 29 Dec 2025."},{"key":"533_CR32","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jgar.2024.06.008","volume":"38","author":"BA Martinez-Guerra","year":"2024","unstructured":"Martinez-Guerra BA, Xancal-Salvador LF, Esteban-Kenel V, Tello-Mercado AC, Bobadilla-Del-Valle M, Sifuentes-Osornio J, et al. Favourable effect of clavulanic acid on the minimum inhibitory concentrations of cefixime and ceftibuten in ESBL-producing Escherichia coli and Klebsiella pneumoniae. J Glob Antimicrob Resist. 2024;38:212\u20135. https:\/\/doi.org\/10.1016\/j.jgar.2024.06.008.","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"533_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-021-02746-8","volume":"7","author":"EA Lallemand","year":"2021","unstructured":"Lallemand EA, Zemirline C, Toutain PL, Bousquet-Melou A, Ferran AA, Boullier S. Dynamic interactions between cephalexin and macrophages on different Staphylococcus aureus inoculum sizes: a tripartite in vitro model. BMC Vet Res. 2021;7(1):23. https:\/\/doi.org\/10.1186\/s12917-021-02746-8.","journal-title":"BMC Vet Res"},{"issue":"12","key":"533_CR34","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1185\/030079906X148355","volume":"22","author":"PA Giordano","year":"2006","unstructured":"Giordano PA, Elston D, Akinlade BK, Weber K, Notario GF, Busman TA, et al. Cefdinir vs. cephalexin for mild to moderate uncomplicated skin and skin structure infections in adolescents and adults. Curr Med Res Opin. 2006;22(12):2419\u201328. https:\/\/doi.org\/10.1185\/030079906X148355.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"533_CR35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3109\/inf.1972.4.issue-3.11","volume":"4","author":"CO Solberg","year":"1972","unstructured":"Solberg CO, Schreiner A, Digranes A. Cephalexin therapy of lower respiratory tract, soft tissue and bone infections. Scand J Infect Dis. 1972;4(3):241\u20133. https:\/\/doi.org\/10.3109\/inf.1972.4.issue-3.11.","journal-title":"Scand J Infect Dis"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00533-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-025-00533-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00533-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:40:22Z","timestamp":1773931222000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-025-00533-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["533"],"URL":"https:\/\/doi.org\/10.1007\/s40801-025-00533-7","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"3 December 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sunil Panda, Shrinivas Chavan, Sumit Agarwal, Neha Sharma, Parth Bipinkumar, Harshal Chaudhari and Dipak Solanki were study investigators and received funding for the conduct of the study. Supriya Sonowal, Dipak Patil, Pravin Ghadge and Suyog Mehta are full-time employees of Sun Pharma Laboratories Limited. Mandodari Rajurkar, Sapan Behera and Lalit Lakhwani were full-time employees of Sun Pharma Laboratories Limited during the conduct of the study. Sadhna Joglekar was a full-time employee of Sun Pharmaceutical Industries Limited during the conduct of the study. She is currently employed by Novartis. The views expressed in the article are the author\u2019s views and do not necessarily reflect the views or official position of Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Two subgroup analyses of this study were presented at the 34th Congress of the European Society of Clinical Microbiology and Infectious Diseases, held in Barcelona, Spain, from 27 to 30 April, 2024.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior presentation"}},{"value":"The study protocol was approved by institutional ethics committees at each study site prior to study initiation. All patients were required to provide mandatory written informed consent. Good Clinical Practice guidelines, local applicable regulations and the Declaration of Helsinki were followed. Furthermore, this study conformed to all regulations concerning the use of personal data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"To receive the fixed-dose combination of cephalexin extended release and clavulanate potassium during the study, eligible patients were required to provide written informed consent. The patients were informed about the study treatment and the scope of the study, and informed consent was obtained from all participants before the screening procedure. An additional written informed consent was obtained from parents or legally acceptable representatives for patients aged <\u00a018 years.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data substantiating the results of this phase IV study can be obtained from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors made substantial contributions to the conception or design of the work, or the acquisition, analysis or interpretation of data. SP, SC, SA, NS, PB, HC and DS contributed to the study conduct and data acquisition. LL, SM and SJ were involved in designing the study. MR, SB, SS, DP and PG were involved in data interpretation. All authors were involved in revising the manuscript critically for important intellectual content, approved the final version to be published and agreed to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}